Phase 3 randomized, controlled trial of NVL-655 for TKI-naïve patients with advanced ALK-positive non-small cell lung cancer
Latest Information Update: 19 Sep 2024
At a glance
- Drugs Zidesamtinib (Primary) ; Alectinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Sep 2024 New trial record
- 14 Sep 2024 According to a Nuvalent media release, the company plans to initiate the ALKAZAR study in the first half of 2025.